Does HLA-B*2706 protect against ankylosing spondylitis? A meta-analysis

Int J Rheum Dis. 2012 Feb;15(1):8-12. doi: 10.1111/j.1756-185X.2011.01676.x. Epub 2011 Oct 18.

Abstract

The human leukocyte antigen (HLA)-B*2706 is a relatively rare subtype of HLA-B27. In contrast to most HLA-B27 subtypes, some studies have reported HLA-B*2706 to be protective against ankylosing spondylitis (AS). A systematic review and a meta-analysis of available studies was performed to investigate the association of HLA-B*2706 with AS. After literature review a random effect meta-analysis was performed. No studies were found comparing the frequency of HLA-B*2706 in AS patients and controls. Meta-analysis of seven studies using HLA-B27-positive AS patients and controls showed a protective effect of HLA-B*2706 on development of AS in HLA-B27 individuals (odds ratio = 0.128, 95% CI = 0.043-0.378, P < 0.001). The results of the meta-analysis of HLA-B*2706 in HLA-B27-positive patients and controls is preliminary evidence of a protective effect of HLA-B*2706 against AS in the population. There is a clear need for additional studies on HLA-B*2706 in AS. Due to the fact that HLA-B*2706 is more or less restricted to Southeast Asia, researchers in this part of the world may have an essential role in performing these studies.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Case-Control Studies
  • Gene Frequency
  • Genotype
  • HLA-B27 Antigen / genetics*
  • Humans
  • Odds Ratio
  • Phenotype
  • Risk Assessment
  • Risk Factors
  • Spondylitis, Ankylosing / epidemiology
  • Spondylitis, Ankylosing / genetics*
  • Spondylitis, Ankylosing / immunology
  • Spondylitis, Ankylosing / prevention & control*

Substances

  • HLA-B*27:06 antigen
  • HLA-B27 Antigen